A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
2024-07-12 16:06
Sara Selgrade
Hello all, Background Thank you very much for your quick work to comment on the Risky Research Review Act. NIH OLPA has asked us to prioritize comments to flag the most urgent or concerning items and/or those needing clarification. Action Item We have compiled the comments that meet NIH OLPA's request into the attached draft technical assistance document. Please note that NIH OLPA has requested examples, where possible. We have tried to add some examples to emphasize key points, but we welcome any suggestions and/or corrections as needed. We would appreciate your review and any edits by 10am Monday, July 15th. Given the quick turnaround, we are asking the Divisions to review concurrently with the NIAID OD. Please note that NIH OSP, NIH ORS/DOHS, and NIH OER will also be reviewing and providing comments. We will be sure to share with you any consolidated NIH comments that we receive. Thank you for your help with this quick turnaround request. Please let me know if you have any questions. Thanks, Sara
-
Hello all, has asked us to ze We will be sure Please let me know if you have any questions. ) 1AM [AID DEA DART ID DIR-OCGR < VIH/NIAID) [--] i >) E) >; P| >; Billet, ion A number of HHS OpDivs and offices, including any technical comments in the ng the bill on behalf of NIH. Please let me know if Background Thank you very much for your quick work to comment on the Risky Research Review Act. NIH OLPA has asked us to prioritize comments to flag the most urgent or concerning items and/or those needing clarification. Action Item We have compiled the comments that meet NIH OLPA's request into the attached draft technical assistance document. Please note that NIH OLPA has requested examples, where possible. We have tried to add some examples to emphasize key points, but we welcome any suggestions and/or corrections as needed. We would appreciate your review and any edits by 10am Monday, July 15th. Given the quick turnaround, we are asking the Divisions to review concurrently with the NIAID OD. Please note that NIH OSP, NIH ORS/DOHS, and NIH OER will also be reviewing and providing comments. We will be sure to share with you any consolidated NIH comments that we receive. Thank you for your help with this quick turnaround request. Please let me know if you have any questions. Thanks, Sara
-
Hello all, Background Thank you very much for your quick work to comment on the Risky Research Review Act. NIH OLPA has asked us to prioritize comments to flag the most urgent or concerning items and/or those needing clarification. Action Item ze We will be sure Please let me know if you have any questions. ) 1AM [AID DEA DART ID DIR-OCGR < IH/NIAID) [--] i >) E) >; P| >; Billet, ion A number of HHS OpDivs and offices, including any technical comments in the ng the bill on behalf of NIH. Please let me know if We have compiled the comments that meet NIH OLPA's request into the attached draft technical assistance document. Please note that NIH OLPA has requested examples, where possible. We have tried to add some examples to emphasize key points, but we welcome any suggestions and/or corrections as needed. We would appreciate your review and any edits by 10am Monday, July 15th. Given the quick turnaround, we are asking the Divisions to review concurrently with the NIAID OD. Please note that NIH OSP, NIH ORS/DOHS, and NIH OER will also be reviewing and providing comments. We will be sure to share with you any consolidated NIH comments that we receive. Thank you for your help with this quick turnaround request. Please let me know if you have any questions. Thanks, Sara
-
Hello all, Background Thank you very much for your quick work to comment on the Risky Research Review Act. NIH OLPA has asked us to prioritize comments to flag the most urgent or concerning items and/or those needing clarification. Action Item We have compiled the comments that meet NIH OLPA's request into the attached draft technical assistance document. Please note that NIH OLPA has requested examples, where possible. We have tried to add some examples to emphasize key points, but we welcome any suggestions and/or corrections as needed. We will be sure Please let me know if you have any questions. ) 1AM [AID DEA DART ID DIR-OCGR < IH/NIAID) [--] >) E) >; P| >; Billet, ion A number of HHS OpDivs and offices, including any technical comments in the ng the bill on behalf of NIH. Please let me know if wP? We would appreciate your review and any edits by 10am Monday, July 15th. Given the quick turnaround, we are asking the Divisions to review concurrently with the NIAID OD. Please note that NIH OSP, NIH ORS/DOHS, and NIH OER will also be reviewing and providing comments. We will be sure to share with you any consolidated NIH comments that we receive. Thank you for your help with this quick turnaround request. Please let me know if you have any questions. Thanks, Sara
-
Hello all, Background Thank you very much for your quick work to comment on the Risky Research Review Act. NIH OLPA has asked us to prioritize comments to flag the most urgent or concerning items and/or those needing clarification. Action Item We have compiled the comments that meet NIH OLPA's request into the attached draft technical assistance document. Please note that NIH OLPA has requested examples, where possible. We have tried to add some examples to emphasize key points, but we welcome any suggestions and/or corrections as needed. We would appreciate your review and any edits by 10am Monday, July 15th. Given the quick turnaround, we are asking the Divisions to review concurrently with the NIAID OD. Please note that NIH OSP, NIH ORS/DOHS, and NIH OER will also be reviewing and providing comments. We will be sure to share with you any consolidated NIH comments that we receive. Thank you for your help with this quick turnaround request. Please let me know if you have any questions. Thanks, Sara